Global Blood Therapeutics Announces New GBT440 Data in Sickle Cell Disease to be Presented at the American Society of Hematology (ASH) Annual Meeting

Global Blood Therapeutics, Inc. (GBT)

, a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that data from the ongoing Phase 1/2 GBT440-001 study of GBT440 will be presented at the 57(th) American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. Data will include an oral presentation of clinical data from the GBT440-001 study in sickle cell disease (SCD) including data from SCD patients receiving additional dosing regimens beyond those described in the abstract, as well as a poster presentation of pharmacokinetic data. GBT440 is an oral, once-daily therapy for the treatment of SCD that works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT440 blocks polymerization and the resultant sickling of red blood cells (RBCs). With the potential to restore normal hemoglobin function, GBT440 may be capable of modifying the progression of SCD. Currently, GBT440 is being investigated in an ongoing Phase 1/2 clinical trial in both healthy subjects and SCD patients. The abstracts are now available at www.hematology.org. Following are details of the presentations, which will include additional data not currently available in the published abstracts. Oral Session: 114. Hemoglobinopathies, Excluding Thalassemia -- Clinical: Promising Therapies in Sickle Cell Disease Abstract #542: GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease Presenter: Dr. Claire Hemmaway, MA (Hons) Cantab, MBBS, FRCP, FRCPATH, Queens Hospital, Essex, United Kingdom Session Date: Monday, December 7, 2015 Session Time: 10:30 a.m. -- 12:00 p.m. Eastern Time (ET) Presentation Time: 10:45 a.m. ET Location: Orange County Convention Center, W340 Poster Session: 113. Hemoglobinopathies, Excluding Thalassemia -- Basic and Translational Science: Poster II Abstract #2172: GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species Session Date/Time: Sunday, December 6, 2015, 6 -- 8 p.m. ET Location: Orange County Convention Center, Hall A